These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37750664)
1. Selenomethionine suppresses head and neck squamous cell carcinoma progression through TopBP1/ATR and TCAB1 signaling. Zhang B; Wei X; Li J Histol Histopathol; 2024 Jul; 39(7):877-887. PubMed ID: 37750664 [TBL] [Abstract][Full Text] [Related]
2. ATR inhibition sensitizes HPV Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. Liu K; Graves JD; Lin FT; Lin WC J Biol Chem; 2021; 296():100382. PubMed ID: 33556369 [TBL] [Abstract][Full Text] [Related]
4. CD147 promotes progression of head and neck squamous cell carcinoma via NF-kappa B signaling. Yu B; Zhang Y; Wu K; Wang L; Jiang Y; Chen W; Yan M J Cell Mol Med; 2019 Feb; 23(2):954-966. PubMed ID: 30421493 [TBL] [Abstract][Full Text] [Related]
5. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma. Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178 [TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of the BRCA1 C terminus (BRCT) repeat inhibitor of hTERT (BRIT1) protein coordinates TopBP1 protein recruitment and amplifies ataxia telangiectasia-mutated and Rad3-related (ATR) Signaling. Zhang B; Wang E; Dai H; Shen J; Hsieh HJ; Lu X; Peng G J Biol Chem; 2014 Dec; 289(49):34284-95. PubMed ID: 25301947 [TBL] [Abstract][Full Text] [Related]
7. TCAB1: a potential target for diagnosis and therapy of head and neck carcinomas. Sun CK; Luo XB; Gou YP; Hu L; Wang K; Li C; Xiang ZT; Zhang P; Kong XL; Zhang CL; Yang Q; Li J; Xiao LY; Li Y; Chen QM Mol Cancer; 2014 Jul; 13():180. PubMed ID: 25070141 [TBL] [Abstract][Full Text] [Related]
8. Common motifs in ETAA1 and TOPBP1 required for ATR kinase activation. Thada V; Cortez D J Biol Chem; 2019 May; 294(21):8395-8402. PubMed ID: 30940728 [TBL] [Abstract][Full Text] [Related]
9. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response. Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway. Li K; Peng S; Li Z; Lai Y; Wang Q; Tao Y; Wu W; Zhou Q; Gao Z; Chen J; Li H; Cai W; Guo Z; Huang H Aging (Albany NY); 2020 May; 12(10):9948-9958. PubMed ID: 32459662 [TBL] [Abstract][Full Text] [Related]
11. The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines. Schnoell J; Sparr C; Al-Gboore S; Haas M; Brkic FF; Kadletz-Wanke L; Heiduschka G; Jank BJ Invest New Drugs; 2023 Dec; 41(6):842-850. PubMed ID: 37934325 [TBL] [Abstract][Full Text] [Related]
12. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma. Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962 [TBL] [Abstract][Full Text] [Related]
13. Quantitative phosphoproteomics reveals mitotic function of the ATR activator ETAA1. Bass TE; Cortez D J Cell Biol; 2019 Apr; 218(4):1235-1249. PubMed ID: 30755469 [TBL] [Abstract][Full Text] [Related]
14. The Notch inhibitor, FLI-06, increases the chemosensitivity of head and neck Squamous cell carcinoma cells to taxanes-based treatment. Czerwonka A; Kałafut J; Wang S; Anameric A; Przybyszewska-Podstawka A; Toriseva M; Nees M Biomed Pharmacother; 2024 Aug; 177():116822. PubMed ID: 38906029 [TBL] [Abstract][Full Text] [Related]
15. ATR activation is regulated by dimerization of ATR activating proteins. Thada V; Cortez D J Biol Chem; 2021; 296():100455. PubMed ID: 33636182 [TBL] [Abstract][Full Text] [Related]
16. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323 [TBL] [Abstract][Full Text] [Related]
17. Livin enhances chemoresistance in head and neck squamous cell carcinoma. Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Targeting of the GLS1-c-Myc Positive Feedback Loop Suppresses Glutaminolysis and Inhibits Progression of Head and Neck Cancer. Yang J; Chen F; Lang L; Yang F; Fu Z; Martinez J; Cho A; Saba NF; Teng Y Cancer Res; 2024 Oct; 84(19):3223-3234. PubMed ID: 39024547 [TBL] [Abstract][Full Text] [Related]
19. PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling. Zheng A; Li F; Chen F; Zuo J; Wang L; Wang Y; Chen S; Xiao B; Tao Z Oncol Rep; 2019 May; 41(5):2833-2843. PubMed ID: 30864729 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of LINC00460 decreases STC2 and promotes autophagy of head and neck squamous cell carcinoma by up-regulating microRNA-206. Xue K; Li J; Nan S; Zhao X; Xu C Life Sci; 2019 Aug; 231():116459. PubMed ID: 31075234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]